{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Reflux+Disease%28GERD%29&page=13",
    "query": {
      "condition": "Gastroesophageal Reflux Disease(GERD)",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 452,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Reflux+Disease%28GERD%29&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Reflux+Disease%28GERD%29&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T22:27:49.950Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00251732",
      "title": "Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease"
      ],
      "interventions": [
        {
          "name": "Standard dose (once daily) PPI plus low-dose antidepressant",
          "type": "DRUG"
        },
        {
          "name": "Double dose PPI plus evening placebo",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole , placebo, placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 150,
      "start_date": "2005-03",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2010-08-19",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00251732"
    },
    {
      "nct_id": "NCT00658528",
      "title": "Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease (GERD)"
      ],
      "interventions": [
        {
          "name": "Rabeprazole sodium",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1061,
      "start_date": "2008-02",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-12-21",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00658528"
    },
    {
      "nct_id": "NCT01095133",
      "title": "Do Acid Sensing Ion Channels Contribute to Heartburn?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease",
        "Heartburn"
      ],
      "interventions": [
        {
          "name": "Amiloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-03",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2012-09-20",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01095133"
    },
    {
      "nct_id": "NCT05874726",
      "title": "Biological Sample Repository for Gastrointestinal Disorders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity",
        "Obesity, Morbid",
        "Obesity, Primary",
        "Gastro-Intestinal Disorder",
        "Overweight and Obesity",
        "Overweight",
        "Overweight or Obesity",
        "Diabetes Type 2",
        "Diabetes Mellitus",
        "Diabetes Mellitus, Type 2",
        "Hypertension",
        "Hyperlipidemias",
        "Sleep Apnea",
        "GERD",
        "Gastroesophageal Reflux",
        "Musculoskeletal Pain Disorder",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Blood Collection",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Urine Collection",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Tissue Sample Collection",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Pichamol Jirapinyo, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2023-07-19",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05874726"
    },
    {
      "nct_id": "NCT01129778",
      "title": "Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Barrett Esophagus",
        "Gastroesophageal Reflux"
      ],
      "interventions": [
        {
          "name": "Zegerid (proton pump inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Bravo pH monitoring",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 27,
      "start_date": "2009-11",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2017-06-06",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129778"
    },
    {
      "nct_id": "NCT02395471",
      "title": "Cytosponge Adequacy Study Evaluation II",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Barrett's Esophagus",
        "GERD"
      ],
      "interventions": [
        {
          "name": "Cytosponge™ Cell Collection Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medtronic - MITG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2015-08",
      "completion_date": "2018-06-01",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02395471"
    },
    {
      "nct_id": "NCT01696734",
      "title": "Domperidone in Treating Patients With Gastrointestinal Disorders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Digestive System Disorder",
        "Dyspepsia",
        "Esophagitis",
        "Gastroesophageal Reflux Disease",
        "Gastroparesis",
        "Heartburn",
        "Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "Domperidone",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2012-10-23",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01696734"
    },
    {
      "nct_id": "NCT00410592",
      "title": "Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease"
      ],
      "interventions": [
        {
          "name": "Esomeprazole 40mg",
          "type": "DRUG"
        },
        {
          "name": "Pantoprazole 40mg",
          "type": "DRUG"
        },
        {
          "name": "Lansoprazole 30mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 90,
      "start_date": "2006-10",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2009-03-11",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 7,
      "location_summary": "Anaheim, California • Orange, California • San Diego, California + 4 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00410592"
    },
    {
      "nct_id": "NCT04253392",
      "title": "RETHINK REFLUX Registry",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastroesophageal Reflux"
      ],
      "interventions": [
        {
          "name": "LINX Reflux Management System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Ethicon Endo-Surgery",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "21 Years to 99 Years"
      },
      "enrollment_count": 500,
      "start_date": "2020-07-08",
      "completion_date": "2032-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 21,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 18 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04253392"
    },
    {
      "nct_id": "NCT04846010",
      "title": "Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sequelae of; Infection",
        "Post Infection Glomerulonephritis",
        "Post-Infectious Peripheral Neuralgia",
        "Post-Infectious Disorder (Disorder)",
        "Post-Infectious Arthritis",
        "Post-Infectious Polyneuritis",
        "Post-Infectious Parkinsonism",
        "Post-Infectious Hypothyroidism",
        "Post Infectious Osteoarthritis",
        "Anxiety Disorders",
        "Depression",
        "Depression, Anxiety",
        "Depression, Bipolar",
        "Insomnia",
        "GERD",
        "Gastro Esophageal Reflux",
        "Hepatitis",
        "Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "PurWet",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "FurFat",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PurApo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PurPhl",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PurClo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PurInf",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Smoliv",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "All Natural Medicine Clinic, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2000,
      "start_date": "2021-03-01",
      "completion_date": "2022-10-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-26",
      "last_synced_at": "2026-10-27T22:27:49.950Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04846010"
    }
  ]
}